Research programme: cystic fibrosis transmembrane conductance regulator modulators - Galapagos/AbbVie

Drug Profile

Research programme: cystic fibrosis transmembrane conductance regulator modulators - Galapagos/AbbVie

Alternative Names: Cystic fibrosis therapy research programme - Cystic Fibrosis Foundation/Galapagos; GLPG-2665

Latest Information Update: 30 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cystic Fibrosis Foundation Therapeutics; Galapagos NV
  • Developer AbbVie; Galapagos NV
  • Class Small molecules
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cystic fibrosis

Most Recent Events

  • 30 Oct 2018 Preclinical development in Cystic-fibrosis is ongoing in Belgium (PO)
  • 24 Oct 2018 AbbVie obtains exclusive worldwide rights to develop and commercialise therapies in Cystic fibrosis
  • 15 Oct 2015 Early research in Cystic fibrosis (Combination therapy) in Belgium (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top